An increasing number of patients suffering from severe chronic rhinosinusitis with nasal polyps (CRSwNP) is being exposed to COVID-19. In order to improve patient outcomes in these individuals, companies in the acute viral rhinosinusitis treatment market are increasing their output capacities in dupilumab. Dupilumab is associated with improvement in sinonasal function, which is essential for initially tackling coronavirus.
Dupilumab helps to improve nasal symptoms such as congestion, thus positively affecting the upper respiratory tract. Manufacturers in the acute viral rhinosinusitis treatment market are boosting their production capabilities for other treatments such as nasal corticosteroids and decongestants apart from dupilumab to reduce morbidity and mortality rates amid the ongoing pandemic. The completion of the treatment with dupilumab is recommended, since interruption in the therapy could lead to the progression of rhinosinusitis and worsening of common comorbidities including asthma.
The acute viral rhinosinusitis treatment market is projected to surpass US$ 3.16 Bn by 2031. However, it has been found that in many cases, antibiotics do not prevent the complications of bacterial acute rhinosinusitis (ABRS). This has led to the growing awareness about individual considerations, and taking into account the adverse effects and drug resistances before prescribing antibiotics.
On the other hand, individualized use of intranasal corticoids has proven to be useful in post-vital acute rhinosinusitis (ARS). Manufacturers are bolstering their production capabilities in over-the-counter analgesics and saline nasal irrigation for the treatment of ARS.
Companies in the acute viral rhinosinusitis treatment market are increasing the availability of amoxicillin and clavulanate as a means of appropriate initial therapy for ABRS patients who do not have risk factors for resistance. The combination of amoxicillin and clavulanate is prescribed for children compared to adults. However, there is an increasing emergence of antimicrobial resistance among respiratory pathogens. Hence, manufacturers in the acute viral rhinosinusitis treatment market are increasing their R&D for routine conjugated pneumococcal vaccination in children, which has changed the spectrum of bacterial infection.
The high dose of amoxicillin and clavulanate is being recommended for patients at high risk of pneumococcal resistance. The increasing microbial resistance to antibiotics is leading to the popularity of either amoxicillin or amoxicillin-clavulanate for the treatment of ABRS.
Nasal saline irrigation is found to effectively remove or reduce the burden of debris and pathogens locally from the nares, resulting in symptomatic relief. Companies in the acute viral rhinosinusitis treatment market are increasing their output capacities in topical intranasal therapies to reduce congestion in patients. Topical corticosteroid nasal sprays help to reduce mucosal inflammation, thus reducing stenosis of the sinus drainage pathways. As such, nasal corticosteroids are expected to dominate the second highest revenue among all treatment types in the acute viral rhinosinusitis treatment market.
On the other hand, topical antihistamine can help lower inflammation and irritation of the mucosa, while reducing edema in the nasal passages and opening up the sinus ostia.
Analysts’ Viewpoint
Apart from boosting production of dupilumab and other medications, special epidemic situations such as the ongoing coronavirus pandemic are requiring strict recommendations including social distancing and home confinement. The acute viral rhinosinusitis treatment market is projected to grow at a CAGR of 5.3% during the forecast period. This is evident since the economic burden of ARS is incredibly high, owing to a large number of medical visits. Moreover, misuse of diagnostic testing and overuse of medications lead to high indirect costs. Hence, stakeholders and healthcare providers need to create awareness that ARS is a self-resolving and mild disease that can be treated with the help of individual consideration for medicines.
Acute viral rhinosinusitis treatment market is projected to surpass US$ 3.16 Bn by 2031
Acute viral rhinosinusitis treatment market is projected to expand at a CAGR of 5.3% from 2021 to 2031
Acute viral rhinosinusitis treatment market is driven by increase in incidence of mucosal inflammation leading to rhinosinusitis
North America dominated the global acute viral rhinosinusitis treatment market in 2020, and the trend is anticipated to continue during the forecast period.
Key players in the global acute viral rhinosinusitis treatment market include Sun Pharmaceutical Industries, Inc., Pfizer, Inc., Janssen Pharmaceuticals, Inc. (Johnson & Johnson), Fresenius Kabi USA, LLC, Dr. Reddy's Laboratories, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Acute Viral Rhinosinusitis Treatment Market
4. Market Overview
4.1. Introduction & Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, 2017–2031
5. Market Outlook
5.1. Clinical Trials & Regulatory Approvals Analysis
5.2. List of Brand / Product Approved
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.4. Technological Advancements
5.5. Disease Prevalence & Incidence
6. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Treatment
6.1. Introduction & Definition
6.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
6.2.1. Saline Nasal Spray
6.2.2. Nasal Corticosteroids
6.2.2.1. Fluticasone
6.2.2.2. Budesonide
6.2.2.3. Mometasone
6.2.2.4. Others
6.2.3. Decongestants
6.2.3.1. Topical Decongestants
6.2.3.2. Systemic Decongestants
6.2.4. NSAIDs
6.2.4.1. Acetaminophen
6.2.4.2. Ibuprofen
6.2.4.3. Aspirin
6.2.4.4. Others
6.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration
7. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
7.2.1. Acute Viral Rhinosinusitis Treatment
7.2.1.1. Topical
7.2.1.2. Nasal
7.2.1.3. Oral
7.2.1.4. Injectable
7.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Route of Administration
8. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
8.2.1. Acute Viral Rhinosinusitis Treatment
8.2.1.1. Online Pharmacies
8.2.1.2. Retail Pharmacies
8.2.1.3. Hospital Pharmacies
8.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Distribution Channel
9. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Infection Type
9.1. Introduction & Definition
9.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
9.2.1. Rhinovirus (Picornavirus)
9.2.2. Non-Rhinovirus
9.2.2.1. Influenza
9.2.2.2. Enterovirus
9.2.2.3. Adenovirus
9.2.2.4. Others
9.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Infection Type
10. Global Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Global Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Global Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis, by Region
11. North America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
11.1. Introduction
11.2. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
11.2.1. Saline Nasal Spray
11.2.2. Nasal Corticosteroids
11.2.2.1. Fluticasone
11.2.2.2. Budesonide
11.2.2.3. Mometasone
11.2.2.4. Others
11.2.3. Decongestants
11.2.3.1. Topical Decongestants
11.2.3.2. Systemic Decongestants
11.2.4. NSAIDs
11.2.4.1. Acetaminophen
11.2.4.2. Ibuprofen
11.2.4.3. Aspirin
11.2.4.4. Others
11.2.5. Others
11.3. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
11.3.1. Acute Viral Rhinosinusitis Treatment
11.3.1.1. Topical
11.3.1.2. Nasal
11.3.1.3. Oral
11.3.1.4. Injectable
11.4. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
11.4.1. Acute Viral Rhinosinusitis Treatment
11.4.1.1. Online Pharmacies
11.4.1.2. Retail Pharmacies
11.4.1.3. Hospital Pharmacies
11.5. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
11.5.1. Rhinovirus (Picornavirus)
11.5.2. Non-Rhinovirus
11.5.2.1. Influenza
11.5.2.2. Enterovirus
11.5.2.3. Adenovirus
11.5.2.4. Others
11.6. North America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. North America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
11.7.1. By Treatment
11.7.2. By Route of Administration
11.7.3. By Distribution Channel
11.7.4. Infection Type
11.7.5. By Country
12. Europe Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
12.1. Introduction
12.2. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
12.2.1. Saline Nasal Spray
12.2.2. Nasal Corticosteroids
12.2.2.1. Fluticasone
12.2.2.2. Budesonide
12.2.2.3. Mometasone
12.2.2.4. Others
12.2.3. Decongestants
12.2.3.1. Topical Decongestants
12.2.3.2. Systemic Decongestants
12.2.4. NSAIDs
12.2.4.1. Acetaminophen
12.2.4.2. Ibuprofen
12.2.4.3. Aspirin
12.2.4.4. Others
12.2.5. Others
12.3. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
12.3.1.1. Topical
12.3.1.2. Nasal
12.3.1.3. Oral
12.3.1.4. Injectable
12.4. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
12.4.1.1. Online Pharmacies
12.4.1.2. Retail Pharmacies
12.4.1.3. Hospital Pharmacies
12.5. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
12.5.1. Rhinovirus (Picornavirus)
12.5.2. Non-Rhinovirus
12.5.2.1. Influenza
12.5.2.2. Enterovirus
12.5.2.3. Adenovirus
12.5.2.4. Others
12.6. Europe Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Europe Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
12.7.1. By Treatment
12.7.2. By Route of Administration
12.7.3. By Distribution Channel
12.7.4. By Infection Type
12.7.5. By Country/Sub-region
13. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
13.1. Introduction
13.2. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
13.2.1. Saline Nasal Spray
13.2.2. Nasal Corticosteroids
13.2.2.1. Fluticasone
13.2.2.2. Budesonide
13.2.2.3. Mometasone
13.2.2.4. Others
13.2.3. Decongestants
13.2.3.1. Topical Decongestants
13.2.3.2. Systemic Decongestants
13.2.4. NSAIDs
13.2.4.1. Acetaminophen
13.2.4.2. Ibuprofen
13.2.4.3. Aspirin
13.2.4.4. Others
13.2.5. Others
13.3. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
13.3.1.1. Topical
13.3.1.2. Nasal
13.3.1.3. Oral
13.3.1.4. Injectable
13.4. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
13.4.1.1. Online Pharmacies
13.4.1.2. Retail Pharmacies
13.4.1.3. Hospital Pharmacies
13.5. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
13.5.1. Rhinovirus (Picornavirus)
13.5.2. Non-Rhinovirus
13.5.2.1. Influenza
13.5.2.2. Enterovirus
13.5.2.3. Adenovirus
13.5.2.4. Others
13.6. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Asia Pacific Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
13.7.1. By Treatment
13.7.2. By Route of Administration
13.7.3. By Distribution Channel
13.7.4. Infection Type
13.7.5. By Country/Sub-region
14. Latin America Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
14.1. Introduction
14.2. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
14.2.1. Saline Nasal Spray
14.2.2. Nasal Corticosteroids
14.2.2.1. Fluticasone
14.2.2.2. Budesonide
14.2.2.3. Mometasone
14.2.2.4. Others
14.2.3. Decongestants
14.2.3.1. Topical Decongestants
14.2.3.2. Systemic Decongestants
14.2.4. NSAIDs
14.2.4.1. Acetaminophen
14.2.4.2. Ibuprofen
14.2.4.3. Aspirin
14.2.4.4. Others
14.2.5. Others
14.3. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
14.3.1.1. Topical
14.3.1.2. Nasal
14.3.1.3. Oral
14.3.1.4. Injectable
14.4. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
14.4.1.1. Online Pharmacies
14.4.1.2. Retail Pharmacies
14.4.1.3. Hospital Pharmacies
14.5. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
14.5.1. Rhinovirus (Picornavirus)
14.5.2. Non-Rhinovirus
14.5.2.1. Influenza
14.5.2.2. Enterovirus
14.5.2.3. Adenovirus
14.5.2.4. Others
14.6. Latin America Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Latin America Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
14.7.1. By Treatment
14.7.2. By Route of Administration
14.7.3. By Distribution Channel
14.7.4. Infection Type
14.7.5. By Country/Sub-region
15. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Analysis and Forecast
15.1. Introduction
15.2. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
15.2.1. Saline Nasal Spray
15.2.2. Nasal Corticosteroids
15.2.2.1. Fluticasone
15.2.2.2. Budesonide
15.2.2.3. Mometasone
15.2.2.4. Others
15.2.3. Decongestants
15.2.3.1. Topical Decongestants
15.2.3.2. Systemic Decongestants
15.2.4. NSAIDs
15.2.4.1. Acetaminophen
15.2.4.2. Ibuprofen
15.2.4.3. Aspirin
15.2.4.4. Others
15.2.5. Others
15.3. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
15.3.1.1. Topical
15.3.1.2. Nasal
15.3.1.3. Oral
15.3.1.4. Injectable
15.4. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
15.4.1. Acute Viral Rhinosinusitis Treatment
15.4.1.1. Online Pharmacies
15.4.1.2. Retail Pharmacies
15.4.1.3. Hospital Pharmacies
15.5. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
15.5.1. Rhinovirus (Picornavirus)
15.5.2. Non-Rhinovirus
15.5.2.1. Influenza
15.5.2.2. Enterovirus
15.5.2.3. Adenovirus
15.5.2.4. Others
15.6. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Middle East & Africa Acute Viral Rhinosinusitis Treatment Market Attractiveness Analysis
15.7.1. By Treatment
15.7.2. By Route of Administration
15.7.3. By Distribution Channel
15.7.4. By Infection Type
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Position Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. Sun Pharmaceutical Industries, Inc.
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Growth Strategies
16.2.1.3. SWOT Analysis
16.2.2. Pfizer Inc.
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Growth Strategies
16.2.2.3. SWOT Analysis
16.2.3. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Growth Strategies
16.2.3.3. SWOT Analysis
16.2.4. Fresenius Kabi USA, LLC.
16.2.4.1. Company Overview (HQ, Business Segments)
16.2.4.2. Growth Strategies
16.2.4.3. SWOT Analysis
16.2.5. Dr. Reddy's Laboratories, Inc.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Growth Strategies
16.2.5.3. SWOT Analysis
16.2.6. Novartis AG
16.2.6.1. Company Overview (HQ, Business Segments)
16.2.6.2. Growth Strategies
16.2.6.3. SWOT Analysis
16.2.7. Teva Pharmaceutical Industries Ltd.
16.2.7.1. Company Overview (HQ, Business Segments)
16.2.7.2. Growth Strategies
16.2.7.3. SWOT Analysis
16.2.8. Sanofi
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Growth Strategies
16.2.8.3. SWOT Analysis
16.2.9. Abbott Laboratories
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Growth Strategies
16.2.9.3. SWOT Analysis
16.2.10. Bayer AG
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Growth Strategies
16.2.10.3. SWOT Analysis
16.2.11. Eli Lilly And Company
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Growth Strategies
16.2.11.3. SWOT Analysis
16.2.12. Bristol-Myers Squibb
16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.12.2. Growth Strategies
16.2.12.3. SWOT Analysis
16.2.13. Merck & Co, Inc.
16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.13.2. Growth Strategies
16.2.13.3. SWOT Analysis
16.2.14. AstraZeneca Plc
16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.14.2. Growth Strategies
16.2.14.3. SWOT Analysis
16.2.15. Amneal Pharmaceuticals LLC
16.2.15.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.15.2. Growth Strategies
16.2.15.3. SWOT Analysis
16.2.16. GlaxoSmithKline plc
16.2.16.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.16.2. Growth Strategies
16.2.16.3. SWOT Analysis
16.2.17. Aurobindo Pharma
16.2.17.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.17.2. Growth Strategies
16.2.17.3. SWOT Analysis
16.2.18. Hikma Pharmaceuticals plc
16.2.18.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.18.2. Growth Strategies
16.2.18.3. SWOT Analysis
16.2.19. Wockhardt
16.2.19.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.19.2. Growth Strategies
16.2.19.3. SWOT Analysis
16.2.20. Mylan N.V.
16.2.20.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.20.2. Growth Strategies
16.2.20.3. SWOT Analysis
List of Tables
Table 01: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 02: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 03: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 04: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 05: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 06: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 07: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 08: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 09: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 10: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 11: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 12: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 13: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 14: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 15: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 16: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 17: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 18: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 19: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 21: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 22: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 23: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 24: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 25: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 27: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 28: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 29: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 30: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 31: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 32: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 33: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 34: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 35: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 36: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 37: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 38: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 39: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 40: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 41: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 42: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 43: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 44: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 45: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
Table 46: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 47: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Treatment, 2017–2031
Table 48: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Nasal Corticosteroids, 2017–2031
Table 49: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Decongestants, 2017–2031
Table 50: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by NSAIDs, 2017–2031
Table 51: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031
Table 52: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 53: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Infection Type, 2017–2031
Table 54: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, by Non-rhinovirus, 2017–2031
List of Figures
Figure 01: Global Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 03: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 04: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Saline Nasal Spray, 2017-2031
Figure 05: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Nasal Corticosteroids, 2017-2031
Figure 06: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Decongestants, 2017-2031
Figure 07: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by NSAIDs, 2017-2031
Figure 08: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Others, 2017-2031
Figure 09: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 10: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 11: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Topical, 2017–2031
Figure 12: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Nasal, 2017–2031
Figure 13: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Oral, 2017–2031
Figure 14: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Injectable, 2017–2031
Figure 15: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 16: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 17: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Online Pharmacies, 2017-2031
Figure 18: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Retail Pharmacies, 2017-2031
Figure 19: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Hospital Pharmacies, 2017-2031
Figure 20: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 21: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 22: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Rhinovirus (Picornavirus), 2017–2031
Figure 23: Global Acute Viral Rhinosinusitis Market Value (US$ Mn), by Non-rhinovirus, 2017–2031
Figure 24: Global Acute Viral Rhinosinusitis Market Value Share Analysis, by Region, 2020 and 2031
Figure 25: Global Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Region, 2021–2031
Figure 26: North America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 27: North America Acute Viral Rhinosinusitis Market Value Share, by Country, 2020 and 2031
Figure 28: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country, 2021–2031
Figure 29: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 30: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 31: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 32: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 33: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 34: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 35: North America Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 36: North America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 37: Europe Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 38: Europe Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 39: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 40: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 41: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 42: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 43: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 44: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 45: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 46: Europe Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 47: Europe Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 48: Asia Pacific Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 49: Asia Pacific Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 50: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 51: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 52: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 53: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 54: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 55: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 56: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 57: Asia Pacific Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 58: Asia Pacific Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 59: Latin America Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 60: Latin America Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 61: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 62: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 63: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 64: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 65: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 66: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 67: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 68: Latin America Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 69: Latin America Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031
Figure 70: Middle East & Africa Acute Viral Rhinosinusitis Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 71: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 72: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 73: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Treatment, 2020 and 2031
Figure 74: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Treatment, 2021–2031
Figure 75: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Route of Administration, 2020 and 2031
Figure 76: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Route of Administration, 2021–2031
Figure 77: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 78: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 79: Middle East & Africa Acute Viral Rhinosinusitis Market Value Share Analysis, by Infection Type, 2020 and 2031
Figure 80: Middle East & Africa Acute Viral Rhinosinusitis Market Attractiveness Analysis, by Infection Type, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Acute Viral Rhinosinusitis Treatment Market Trends, 2021-2031
